Cytotoxic drugs were the first form of cancer chemotherapy to be established, but they can have quite severe side effects. Cytotoxics attack all rapidly dividing cells, including healthy cells and cancer cells. They can therefore cause side effects such as loss of hair, damage to the skin and mucosa, and damage to bone marrow, affecting the immune system. For this reason, the focus of some cancer research has moved from cytotoxics to targeted therapeutics, including monoclonal antibodies. Monoclonal antibodies can be very effective in patients who express the appropriate target; however, not all patients do, and some develop resistance. Monoclonal antibodies, like other biologicals, are also very costly. All is not lost for cytotoxics. Because they have been around for so long, there is an abundance of data on their modes of action. Based on these data, researchers have developed newer cytotoxics that are more effective and have fewer side effects, and approaches that deliver cytotoxics more safely or target them to tumours.
the DNA is repaired. Enhanced ability to repair DNA cross links in tumour cells may explain the development of resistance to alkylating agents. 1 The most widely used alkylating agents include the nitrogen mustards cyclophosphamide and ifosfamide, which have bifunctional alkylating metabolites. 8 The platinum-based agent cisplatin was first assessed as an antitumour agent in 1969. Cisplatin forms DNA adducts, leading to cell death, but its mechanism of action is still not clear. 9 Aziridines, such as thiotepa and mitomycin C, are activated by enzymes and form inter-strand cross links. 1 Busulphan is a widely used example of the alkyl sulphonates, and forms inter-strand cross links, as does the nitrosourea carmustine. 1 
Topoisomerase Inhibitors
Topoisomerase inhibitors wind and unwind DNA during DNA replication and protein synthesis, and inhibiting these enzymes leads to cell death. For example, topoisomerase II induces transient double-strand breaks during DNA replication and transcription, and then catalyses strand break repair. Inhibiting topoisomerase II prevents the strand break repair, leading to programmed cell death. 10 For example, the topoisomerase II inhibitor etoposide acts by stabilising the DNA-topoisomerase II complex.
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Topoisomerase I inhibitors, such as camptothecin and camptothecin derivatives, inhibit the relegation stage of the nicking-closing reaction catalysed by topoisomerase I, leaving the enzyme covalently complexed with DNA.

Anthracyclines and Other Cytotoxic Antibiotics
The earliest antitumour antibiotic, actinomycin A, dates back to the 1930s. Actinomycin A was isolated from Streptomyces. Anthracycline antibiotics have a number of targets in the cell. They bind to DNA and intercalate in the major groove of the double helix, which may cause the double helix to unwind by separating purine and pyrimidine bases.
They also bind to RNA, proteins and lipids, interfering with the replication of DNA, the transcription and translation of DNA, and inhibiting enzymes and affecting membrane function. 10 Anthracycline antibiotics also inhibit topoisomerase II, which induces transient double-strand breaks during DNA replication and transcription, and then catalyses strand break repair. Inhibiting topoisomerase II prevents strand break repair, leading to programmed cell death. 10 Anthracenedione antibiotics such as mitoxantrone intercalate into the double helix and act as topoisomerase II inhibitors. 10 Actinomycins, for example actinomycin D, intercalate between base pairs in DNA and lie in the minor groove of DNA. Actinomycin D forms a very stable complex with single-and double-stranded DNA, inhibiting RNA and protein synthesis. 10 Mitomycin C forms DNA inter-strand cross links and inhibits DNA replication, and the bleomycins cause fragmentation of DNA.
10
Antimetabolites
Antimetabolites prevent cell division by being incorporated into nuclear material or by combining with cellular enzymes. 12 Antimetabolites include pyrimidine antimetabolites, such as fluorouracil (5-FU), which inhibit the enzyme thymidine synthase and are incorporated into RNA. 8 Antifolates affect the production of folate compounds and thus inhibit the folate-dependent enzymes required for DNA synthesis. An example is methotrexate, the most widely used antifolate, which is an inhibitor of dihydrofolate reductase, part of the DNA synthesis pathway. 8 
Antimicrotubule or Antitubulin Agents
The taxanes and vinca alkaloids act by disrupting the assembly of microtubules, which are involved in cytokinesis, mitosis and vesicular transport. 8 Paclitaxel was the first taxane on the market, and was isolated from the bark of the Pacific yew tree Taxus brevifolia. Taxanes interrupt cell division and cause cell cycle arrest. 8 Docetaxel is a semi-synthetic analogue of paclitaxel.
The original vinca alkaloids, vincristine and vinblastine, were isolated from Vinca rosea L, the periwinkle plant. These vinca alkaloids interfere with the balance between tubulin and microtubules and prevent mitosis, which triggers apoptosis. 8 Follow-up vinca alkaloids include vindesine and vinorelbine. The End of Cytotoxics? In the 40 years since 1971, when President Nixon announced a war on cancer, the cumulative adult death rate from cancer (adjusted for the size and age of the population) has fallen by less than 5 % despite investments of over US$100 billion. 15 Cytotoxics have been the mainstay of the cancer therapeutics market during that period, but their high toxicity profile and their lack of impact on the death rate have left an opening for a new generation of therapeutics.
Disadvantages of Cytotoxic Agents
There has been a huge growth in the identification and validation of specific tumour targets, particularly through the explosion of the genomic data available. Researchers have responded to this by developing targeted therapeutics, including monoclonal antibodies.
The rationale behind targeted therapeutics is that they home in on specific biomarkers on diseased cells, maximising therapeutic benefit and minimising the effects on healthy cells. 16 Targeted therapeutics can be used as monotherapies or combination therapies with other biologicals or with cytotoxic agents. In 2009, about 30 % of the sales of the top 10 oncology products were monoclonal antibodies 3 and the biological therapeutics market overall is likely to be worth US$53 billion by 2014, 8 with a growth rate of around 7 %. 19 The number of monoclonal antibodies approved for launch has grown since 1997 (see Figure 2 ).
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Mechanism of Action of Monoclonal Antibodies
Monoclonal antibodies have a number of different mechanisms of action. Once they have bound to cancer cells they can activate antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, triggering the immune system to destroy the cells.
Monoclonal antibodies can also be designed to target the growth factors that tumour cells require for growth and development, such as vascular endothelial growth factor (VEGF). For example, bevacizumab targets VEGF, blocking angiogenesis, and is used to treat a range of cancers. 22 Monoclonal antibodies have also been developed to target growth factor receptors, such as the epidermal growth factor receptor (EGFR) family. For example, trastuzumab targets the EGFR human epidermal growth factor receptor 2 (HER2) and is effective in HER2-positive breast cancers; cetuximab targets EGFR, inhibits its activation and is used in colorectal and head and neck cancer.
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Monoclonal antibodies also use a range of other actions, including triggering apoptosis.
Disadvantages of Targeted Therapies
The early monoclonal antibodies were murine and caused problems with immunogenicity, which affected both safety and efficacy. The side effects of monoclonal antibodies are generally just a flu-like response, such as mild-to-moderate fever and chills, or an injection site reaction, and these generally improve after the first administration. Some people may develop an anaphylactic reaction.
This is a hypersensitivity antigen-antibody reaction that can develop three to four hours after administration and may be fatal. 23 Immune responses to monoclonal antibodies can also affect efficacy by reducing therapeutic antibody serum levels. 18 The next step was to create chimeric and humanised forms of monoclonal antibodies, which would combine sequences from mouse and human sources and reduce the problems with immunogenicity.
A number of these are now on the market. 18 Supportive Oncology 20 Davis, 2011. 21 antibodies panitumumab and adalimumab showed immunogenic responses in 1 % and 5 % of patients, respectively, but less than 1 % of patients receiving rituximab, a chimeric monoclonal antibody, showed immunogenicity. 18, 24, 25 Monoclonal antibodies are by nature specific, and while they can be very effective in patients who express the specific target, they are ineffective in patients not carrying the relevant biomarker. For example, only around 25 % of breast cancers are HER2 positive, and patients who are HER2 negative will not respond to trastuzumab. 
Newer Cytotoxics
To address the toxicity and resistance issues associated with platinum-based compounds, some researchers are focusing on organometallic compounds. In a 2011 review by Gasser et al., 7 metallocenes, organometallic complexes, organometallics, metal carbene complexes and metal carbonyl complexes were analysed.
These compounds seem to be stable and are well characterised. They have a range of modes of action, including protein interactions -for example with hormonal receptors, cyclooxygenases and kinasesand novel, metal-specific modes of action. While there do not appear to be any organometallic compounds in clinical trials for cancer, the ferrocene derivative ferrocerone is approved in Russia for anaemia, and ferroquine has undergone phase II trials for malaria. Some tumours develop resistance to taxanes. To address this issue, research is under way into taxane derivatives. 27 Larotaxel is an example of a taxane derivative and, while it has not been approved for launch, it gives an indication of the directions for development.
Larotaxel is a semi-synthetic taxoid prepared from 10-deacetyl baccatin III, a compound extracted from yew trees. In preclinical studies, larotaxel showed activity against multidrug-resistant tumours. Larotaxel showed activity alone and in combination with trastuzumab in patients with metastatic breast cancer, including those with taxane-resistant disease. 27 It was studied in phase III trials in advanced prostate cancer and showed activity but no survival benefit. 28 As part of R&D restructuring, Sanofi-aventis terminated the development of larotaxel in February 2010. 
Combination Regimens
A number of monoclonal antibodies have been licensed or are being studied for use in combination with cytotoxic agents. 12 Examples are presented in Table 2 . 12, 22, 33, 34 The advantage of combination regimens is that responses can improve, resistance is less likely to develop, and doses of cytotoxic agents may be decreased, therefore reducing side effects. Combination therapies may be effective in patients who have stopped responding to single agents.
Targeting Cytotoxics to Tumours
When cytotoxic agents are administered systemically, as little as 5-10 % of the active agent may reach the tumour site, and this can lead to disease relapse, drug resistance 35 and unwanted side effects.
Complexing single cytotoxic agents or combinations of cytotoxic
The End of Cytotoxics? 22 Olver, 2008 ; 33 Vose, et al., 2005. 34 agents with molecules or technologies that target the therapeutics to the tumour could improve responses, slow the development of resistance, and reduce side effects because of reduced systemic exposure. This strategy will also reduce the dose required, which could cut the costs of expensive agents. This could include approaches that target a specific marker or are physically localised to the tumour. Biocompatibles UK has developed a sulfonate-modified polyvinyl alcohol hydrogel matrix called DC Bead ® that can be loaded with cytotoxic agents. The beads are used in transarterial chemoembolisation, which blocks the peripheral blood vessels feeding the tumour and delivers cytotoxic drugs locally. They can also be administered intraperitoneally or intratumourally, and have been studied using doxorubicin, mitoxantrone, irinotecan and topotecan. 
Conclusion
In one form or another, cytotoxics have been used for over 70 years.
Although they have a range of negative side effects, there is an abundance of data on them and they have improved or saved hundreds of thousands of lives. Researchers are working on a range of approaches to improve their toxicity profile, safety and efficacy.
Cytotoxics should remain part of standard and new approaches to treat cancer, as part of delivery systems and pro-drugs, alone and in combination with biological and targeted therapeutic regimens. n
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